Tenofovir Alafenamide.

Area of Science:

• Pharmacology and Therapeutics
• Infectious Diseases
• Antiviral Drug Development

Background:

• Tenofovir alafenamide (TAF) is a newer prodrug of tenofovir, designed to improve upon the safety profile of tenofovir disoproxil fumarate (TDF).
• TAF achieves higher intracellular concentrations of tenofovir with lower serum levels compared to TDF.
• This pharmacokinetic advantage is hypothesized to reduce systemic toxicity associated with tenofovir therapy.

Purpose of the Study:

• To comprehensively review the pharmacology, clinical efficacy, safety profile, and therapeutic positioning of tenofovir alafenamide (TAF).
• To evaluate TAF's role in the management of HIV-1 infection based on available scientific evidence.

Main Methods:

• Literature search of PubMed (2004-2016) using keywords: tenofovir alafenamide, TAF, and GS-7340.
• Inclusion of in vitro studies, Phase I-III clinical trials, and pharmacokinetic/pharmacodynamic evaluations.
• Review of conference abstracts from major infectious diseases and HIV meetings.

Main Results:

• Clinical trials confirm TAF's efficacy is similar to TDF in achieving virological suppression in HIV-1 patients.
• TAF-containing regimens demonstrate significant improvements in kidney function markers and bone mineral density compared to TDF.
• Three TAF-containing combination products are FDA-approved for HIV-1 management, with one recommended for initial therapy.

Conclusions:

• Tenofovir alafenamide (TAF) is an effective nucleotide reverse transcriptase inhibitor for HIV-1 treatment.
• TAF exhibits comparable efficacy to TDF but with a superior safety profile, particularly regarding nephrotoxicity and bone density.
• TAF represents a significant advancement in HIV therapy, offering improved patient outcomes and tolerability.